Extended treatment with IN PACAP38 for 3 months in a mouse model of AD decreased the amount of soluble amyloid β; decreased gene expression of receptor for advanced glycation end products (RAGE), a protein involved in chronic inflammatory diseases, diabetes, and AD; and improved memory in the novel object recognition test [88]. The gene discussed is AGER; the disease is Alzheimer disease.